12 Yue 3 dies, studium "De SCALPELLUM" published online, quia CD30 -positive foris periphericis T -cell lymphoma aegros, hoc rituximab, Cyclophosphamide, et doxorubicin valium ( CHP A + ) Potius quam cyclophosphamide, doxorubicin, et vincristine valium ( PRAESECO ).
Steven Horwitz , MD, ex Memorial Sloan Kettering Cancer Centrum in urbe New York et collegae duplicem caecum, placebo continentem, activam continentem periodum 3 studium involvendi 452 aegros ex 132 locis in 17 terris egerunt. Hi aegroti CD30- positivi lymphoma periphericum T- cellum sine curatione praecedente. Aegroti cum 1 : 1 temere proportio ratio, admittit A+CHP vel CHOP 6 sustentatorum vel . 8° 21 dies est cyclus.
In investigatores invenit media, liberum progressum salvos (PFS) in A + CHP in dolor coetus et coetus atque 48.2 20.8 menses erant, respectively. Incidentia parte effectus similis erat inter duos circulos, inter neutropenia lingua sed torpet (quod XVIII% XV%, respective) et periphericis neuropathia (et LII% LV%, respective). IV% quod III% of Africa gesta sunt adversa exitiale aegris, respectively.
In the CHP to add this cetuximab can improve progression-free and overall survival without increasing toxicity, the study supports the A + CHP for many CD30 positive outer peripheral T new standard treatment for lymphoma aegros.
